

---

## Unlocking Value with a Fractional Chief Medical Officer

---

### Strategic Leadership. Real Agility. Measurable Impact.

In today's biotech landscape, the line between progress and delay can be razor thin. Promising science alone isn't enough — success depends on having the right medical leadership to shape your early development strategy, guide investment decisions, and connect your science with the real world.

#### Key Questions for Growing Biotechs

1. **Is your target product profile clearly aligned with patient, regulatory and payer needs?**
2. **Are your early studies designed to impress investors and withstand regulatory scrutiny?**
3. **If development slows, are you equipped to adapt without fixed overheads?**

For many early-stage companies, a fractional Chief Medical Officer (fCMO) provides the strategic, flexible leadership that bridges these gaps — accelerating progress from discovery to proof of concept.

### From Discovery to Proof of Concept

tranScrip's fCMOs are more than consultants — they become embedded partners in your journey, bringing decades of senior pharmaceutical and biotech experience to shape, de-risk and deliver your clinical strategy.

#### A fCMO will:

- Refine your Target Product Profile (TPP)
- Develop your translation and biomarker strategy
- Lead indication evaluation and clinical development planning
- Design and oversee first-in-human and proof-of-concept studies
- Integrate PK/PD modelling and define safety windows
- Engage with key opinion leaders, regulators, and payers
- Develop key 'go/no go' inflection points in clinical development

Every decision they guide ensures your programme is scientifically sound, strategically aligned, and commercially compelling.

## Why tranScrip

tranScrip's fractional CMO service gives you immediate access to senior, industry-tested pharmaceutical physicians — all GMC-registered, with many holding FFPM and CCT accreditation for the highest level of credibility.

Each fCMO is backed by tranScrip's full multidisciplinary team across regulatory affairs, clinical operations, pharmacology, safety, and market access. Meaning you don't just get a CMO; you gain a CMO supported by an organisation — a trusted network delivering expertise across every stage of development.

This flexible, scalable model provides the leadership you need for milestones, investor interactions, programme recovery, or ongoing oversight, without the cost or commitment of a permanent CMO.

## Flexible Leadership for Dynamic Biotechs

We understand that early-stage companies face uncertainty, from shifting funding timelines to evolving data. Our fractional model gives you access to top-tier medical leadership only when you need it, allowing you to scale support as your programme evolves.

Whether you require strategic input for an investor round, leadership during first-in-human trials, or an interim C-suite presence, tranScrip's fCMOs provide continuity, credibility, and control — without fixed overheads.

## The Cost of Not Having a CMO

Without senior medical leadership, early-stage biotechs risk:

- Misaligned study design and wasted spend
- Delayed regulatory engagement
- Missed opportunities to attract investors or partners
- Loss of scientific momentum during development pauses
- Loss of flexibility in response to emerging clinical trial data and changing competitor and regulatory landscapes

A tranScrip fCMO helps you avoid these pitfalls — keeping your science investor-ready, regulatory-aligned, and strategically on course.

## From TRANslation to preSCRIPtion

Every day without the right medical direction is a missed opportunity to accelerate your journey to patients.

Let's discuss how tranScrip's fractional Chief Medical Officer service can strengthen your leadership, de-risk your development, and unlock the full value of your innovation.

Visit  
[transcrip-group.com](https://transcrip-group.com)

Email  
[info@transcrip-group.com](mailto:info@transcrip-group.com)